NASDAQ:BDSX Biodesix (BDSX) Stock Price, News & Analysis → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free BDSX Stock Alerts $1.58 +0.01 (+0.64%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.56▼$1.5850-Day Range$1.21▼$1.5852-Week Range$1.03▼$2.21Volume50,929 shsAverage Volume138,384 shsMarket Capitalization$180.64 millionP/E RatioN/ADividend YieldN/APrice Target$3.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biodesix alerts: Email Address Biodesix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside96.8% Upside$3.10 Price TargetShort InterestHealthy0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 13 Articles This WeekInsider TradingSelling Shares$8,025 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector400th out of 921 stocksMedical Laboratories Industry10th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingBiodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiodesix has only been the subject of 3 research reports in the past 90 days.Read more about Biodesix's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of Biodesix have been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently increased by 9.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDSX. Previous Next 3.1 News and Social Media Coverage News SentimentBiodesix has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Biodesix this week, compared to 1 article on an average week.MarketBeat Follows4 people have added Biodesix to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,025.00 in company stock.Percentage Held by Insiders63.80% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.96% of the stock of Biodesix is held by institutions.Read more about Biodesix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($0.44) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biodesix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. About Biodesix Stock (NASDAQ:BDSX)Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Read More BDSX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDSX Stock News HeadlinesMay 15 at 1:16 AM | americanbankingnews.comTD Cowen Begins Coverage on Biodesix (NASDAQ:BDSX)May 13, 2024 | markets.businessinsider.comBuy Rating Justified by Biodesix’s Market Leadership and Strong Growth ProspectsMay 11, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 10, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 PerformanceMay 10, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comBiodesix First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 8, 2024 | investorplace.comBDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comBiodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule ManagementMay 7, 2024 | businesswire.comBiodesix to Participate in the 2024 RBCCM Global Healthcare ConferenceApril 24, 2024 | businesswire.comBiodesix to Report First Quarter 2024 Financial Results on May 8, 2024April 13, 2024 | finance.yahoo.comThe recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)April 9, 2024 | businesswire.comBiodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual MeetingApril 5, 2024 | markets.businessinsider.comS&P 500 Gains Over 1%; GCT Semiconductor Shares Spike HigherApril 5, 2024 | markets.businessinsider.comGold Surges Over 1%; Biodesix Shares PlummetApril 5, 2024 | businesswire.comBiodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private PlacementMarch 25, 2024 | businesswire.comBiodesix Announces New Master Collaborative Research Agreement with Leading US Cancer CenterMarch 4, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call TranscriptMarch 3, 2024 | finance.yahoo.comBiodesix Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 1, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit MarginMarch 1, 2024 | businesswire.comBiodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business HighlightsFebruary 26, 2024 | businesswire.comBiodesix to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 16, 2024 | finance.yahoo.comBiodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024February 16, 2024 | businesswire.comBiodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024February 13, 2024 | finance.yahoo.comBiodesix Inc CEO Scott Hutton Sells 64,390 SharesSee More Headlines Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2024Today5/17/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:BDSX CUSIPN/A CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees217Year FoundedN/APrice Target and Rating Average Stock Price Target$3.10 High Stock Price Target$3.50 Low Stock Price Target$2.80 Potential Upside/Downside+96.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,150,000.00 Net Margins-85.80% Pretax Margin-85.80% Return on Equity-29,379.44% Return on Assets-52.08% Debt Debt-to-Equity Ratio7.69 Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$49.09 million Price / Sales3.69 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-31.60Miscellaneous Outstanding Shares114,690,000Free Float41,516,000Market Cap$181.21 million OptionableOptionable Beta1.15 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Scott Hutton (Age 52)President, CEO & Director Comp: $632kMs. Robin Harper Cowie (Age 44)CFO, Secretary & Treasurer Comp: $390.87kDr. Heinrich RöderFounder & CTOMr. Christopher VazquezVP, Controller & Chief Accounting OfficerMr. Mark DeBlockVice President of SalesMr. Robbie LuntSenior Director of MarketingMs. Jessica OlbrichtSenior Director of Human ResourcesDr. Gary Anthony Pestano Ph.D. (Age 57)Chief Development Officer Ms. Bobbi CoffinChief Growth OfficerDr. James R. Jett M.D.Co-Chief Medical OfficerMore ExecutivesKey CompetitorsPersonalisNASDAQ:PSNLSera PrognosticsNASDAQ:SERAEnzo BiochemNYSE:ENZRenalytixNASDAQ:RNLXExagenNASDAQ:XGNView All CompetitorsInsiders & InstitutionsOracle Investment Management Inc.Sold 30,588 shares on 5/15/2024Ownership: 0.026%Scott HuttonSold 3,764 sharesTotal: $5,570.72 ($1.48/share)Robin Harper CowieSold 980 sharesTotal: $1,450.40 ($1.48/share)Gary Anthony PestanoSold 434 sharesTotal: $642.32 ($1.48/share)Chris VazquezSold 244 sharesTotal: $361.12 ($1.48/share)View All Insider TransactionsView All Institutional Transactions BDSX Stock Analysis - Frequently Asked Questions Should I buy or sell Biodesix stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BDSX shares. View BDSX analyst ratings or view top-rated stocks. What is Biodesix's stock price target for 2024? 5 equities research analysts have issued 1 year price objectives for Biodesix's stock. Their BDSX share price targets range from $2.80 to $3.50. On average, they expect the company's stock price to reach $3.10 in the next twelve months. This suggests a possible upside of 96.8% from the stock's current price. View analysts price targets for BDSX or view top-rated stocks among Wall Street analysts. How have BDSX shares performed in 2024? Biodesix's stock was trading at $1.84 at the beginning of 2024. Since then, BDSX shares have decreased by 14.4% and is now trading at $1.5750. View the best growth stocks for 2024 here. When is Biodesix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our BDSX earnings forecast. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) announced its earnings results on Friday, March, 1st. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm earned $14.67 million during the quarter, compared to the consensus estimate of $15.76 million. Biodesix had a negative trailing twelve-month return on equity of 29,379.44% and a negative net margin of 85.80%. What guidance has Biodesix issued on next quarter's earnings? Biodesix issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $65.0 million-$68.0 million, compared to the consensus revenue estimate of $66.2 million. When did Biodesix IPO? Biodesix (BDSX) raised $76 million in an IPO on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Biodesix's major shareholders? Biodesix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.81%), Oracle Investment Management Inc. (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Charles M Watts, Chris Vazquez, Gary Anthony Pestano, Hany Massarany, Jack W Schuler, John Patience, Kieran O'kane, Matthew Strobeck, Robert William Georgantas III, Robin Harper Cowie, Ryan H Siurek and Scott Hutton. View institutional ownership trends. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BDSX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA ‘DeFi Summer’ Projected!Crypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceThe #1 Investment of the Decade… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
